Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tgAAG76 in RPE65-related retinal degeneration
NCT00643747Phase 2Completed
- Sponsor
- University College London
- Start
- Jan 2007
- Primary completion
- Dec 2014
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tgAAG76 in retinal degeneration, sponsored by University College London. Primary endpoint: Intraocular inflammation at 12 months. Started Jan 2007; status: completed.
02
Drugs
tgAAG76
03
Conditions
retinal degeneration
Beyond the preview
Go deeper on NCT00643747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00643747.